Nl-Fr

View abstract

This abstract is assigned to session Free Paper Session VI: Immunology
Presentation preference Oral presentation
TitleLymphocyte subsets and immune check point receptors after interferon alpha: preliminary findings
Accept poster if oral is not possible ?Yes
PurposeTo evaluate the influence of interferon-alpha treatment on the lymphocyte subsets and immune checkpoint receptor expression levels.
MethodsFour patients on interferon alpha-2a (3MU per day until remission, 3MU every 2nd day after remission) were included. Blood samples were taken before and at the 1st month of treatment. Lymphocyte subsets and immune checkpoint receptors (PD-1, CTLA-4, TIGIT, LAG-3, Tim-3) were analyzed by flow cytometry.
ResultsFour patients were included (3 Behçet’s, 1 Eales; mean age:27.5±9.3 years, 2 male, 2 female). The ratio of CD4 cells (44.4±9.6 vs. 44.2±7.5), CD8 cells (30.7±4.2 vs. 34.5±4.8), CD19 B cells (8.7±1.4 vs. 8.8±4.6), CD3-CD16+CD56+ NK cells (10.4±6.6 vs. 9.3±5.1) and CD3+CD16+CD56+ NKT cells (5.7±3.8 vs. 3.2±0.6) remained at similar levels. But the ratio of Treg cells increased significantly after treatment (5.3±2.8 vs. 14.1±4.3, 0=0.04). There was a trend towards an increased expression of some checkpoint receptors in certain subsets, such as CTLA-4 in CD4+ T cells, PD-1 and Lag-3 in CD8+ T cells.
ConclusionThese results confirmed previous report on Tregs with interferon alpha-2a. The expression of certain checkpoint receptors tended to change in specific subsets. Further work with a larger sample size will better explain these treatment-associated findings.
Conflict of interestNo
Author 1
Last nameESEN
Initials of first name(s)F
DepartmentIMU School of Medicine, Ophthalmology
CityIstanbul
CountryTurkey
Author 2
Last nameTURKYILMAZ
Initials of first name(s)O
DepartmentIMU School of Medicine, Ophthalmology
CityIstanbul
CountryTurkey
Author 3
Last nameAYKUT
Initials of first name(s)V
DepartmentIMU School of Medicine, Ophthalmology
CityIstanbul
CountryTurkey
Author 4
Last nameDENIZ
Initials of first name(s)G
DepartmentIU Aziz Sancar DETAE, Immunology
CityIstanbul
CountryTurkey
Author 5
Last nameOGUZ
Initials of first name(s)H
DepartmentIMU School of Medicine, Ophthalmology
CityIstanbul
CountryTurkey
Author 6
Last nameDIRESKENELI
Initials of first name(s)H
DepartmentMarmara Univ. SOM, Rheumatology
CityIstanbul
CountryTurkey
Author 7
Last nameAKTAS CETIN
Initials of first name(s)E
DepartmentIU Aziz Sancar DETAE, Immunology
CityIstanbul
CountryTurkey